Northern Trust Corp Has $24.22 Million Stake in Twist Bioscience Corporation $TWST

Northern Trust Corp reduced its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 1.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 616,864 shares of the company’s stock after selling 10,785 shares during the period. Northern Trust Corp owned 1.03% of Twist Bioscience worth $24,218,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of TWST. Nuveen LLC acquired a new stake in Twist Bioscience during the 1st quarter worth about $31,960,000. ARK Investment Management LLC grew its holdings in Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock worth $245,045,000 after acquiring an additional 645,730 shares during the period. Citigroup Inc. grew its holdings in Twist Bioscience by 124.1% during the 1st quarter. Citigroup Inc. now owns 206,461 shares of the company’s stock worth $8,106,000 after acquiring an additional 114,338 shares during the period. Lord Abbett & CO. LLC acquired a new stake in Twist Bioscience during the 1st quarter worth about $3,977,000. Finally, Russell Investments Group Ltd. grew its holdings in Twist Bioscience by 1,121.3% during the 1st quarter. Russell Investments Group Ltd. now owns 108,834 shares of the company’s stock worth $4,273,000 after acquiring an additional 99,923 shares during the period.

Insider Activity

In related news, CEO Emily M. Leproust sold 1,678 shares of the firm’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.76, for a total value of $60,005.28. Following the transaction, the chief executive officer owned 645,782 shares of the company’s stock, valued at approximately $23,093,164.32. This trade represents a 0.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 2,449 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,250 shares of company stock worth $193,852. 3.01% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TWST. Evercore ISI set a $46.00 price target on Twist Bioscience in a report on Monday, August 4th. JPMorgan Chase & Co. decreased their price target on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group cut their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Tuesday, May 6th. Robert W. Baird cut their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Finally, Guggenheim reissued a “buy” rating and set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, May 6th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.40.

Twist Bioscience Price Performance

TWST stock opened at $26.97 on Monday. The stock has a market capitalization of $1.63 billion, a PE ratio of -18.60 and a beta of 2.31. The company’s 50-day moving average is $32.75 and its 200-day moving average is $35.45. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. Twist Bioscience Corporation has a 1 year low of $24.28 and a 1 year high of $55.33.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million for the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.